Results of multimodality therapy for unresectable primary liver cancer.
- Author:
Shu-guang CHEN
1
;
Shuang-min ZHANG
;
Hai-tao ZHAO
;
Ning ZHANG
;
Kai HAN
;
Shao-bin WANG
;
Qiang QU
;
Xue WEI
;
Jingan RUI
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Aged, 80 and over; Chemoembolization, Therapeutic; methods; Combined Modality Therapy; Cryosurgery; Female; Follow-Up Studies; Humans; Liver Cirrhosis; complications; therapy; Liver Neoplasms; complications; pathology; therapy; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis
- From: Chinese Journal of Oncology 2006;28(9):709-712
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the therapeutic measures for unresectable primary liver cancer (PLC).
METHODSThe date of 312 unresectable primary liver cancer patients treated from January 1991 to March 2003 were retrospectively analyzed.
RESULTSOf these 312 patients, 73 were treated by cryosurgery-based combined modality therapy, 239 were treated by a TACE-oriented combined modality therapy. 289 patients except 23 were followed for a period of 2 to 156 months. The overall 1-,3- and 5-year survival rate in this series was 74. 0% , 34. 0% and 16. 7% , respectively. The 1-,3-and 5-year survival rate in the cryosurgery group was 64. 4% , 38. 4% and 27. 4% , respectively. The 1-, 3- and 5-year survival rate in the TACE group was 75. 1% , 29. 0% and 10. 0%, respectively.
CONCLUSIONTreatment for the unresectable primary liver cancer should be individualized and combined with suitable therapeutic modalities.
